论文部分内容阅读
目的探讨双歧杆菌三联活菌肠溶胶囊对重症肺炎患者肠黏膜屏障功能的保护作用。方法选取重症肺炎患者66例,随机分为观察组(n=33例)和对照组(n=33例)。两组患者均予以吸氧、抗感染、抗休克和营养支持等常规治疗,必要时行机械通气或血管活性药物。观察组患者加用双歧杆菌三联活菌肠溶胶囊420 mg,3次/d,温水服用或水化后自鼻饲注入。观察两组患者治疗前和治疗14 d后内毒素、二胺氧化酶(DAO)和D-乳酸水平的变化,并比较其临床疗效。结果治疗14 d后,两组患者血清内毒素、DAO和D-乳酸水平均较前明显下降(P<0.01或P<0.05),且观察组下降值明显大于对照组(P<0.05);同时观察组患者的临床总有效率明显高于对照组(χ2=3.88,P<0.05)。结论双歧杆菌三联活菌肠溶胶囊辅助治疗重症肺炎患者具有较好的疗效,能明显降低血清内毒素、DAO和D-乳酸水平,减轻患者内毒素血症和肠黏膜通透性,保护患者肠黏膜屏障功能。
Objective To investigate the protective effect of live bifidobacterium enteric-coated enteric-coated capsules on intestinal mucosal barrier function in patients with severe pneumonia. Methods Sixty-six patients with severe pneumonia were randomly divided into observation group (n = 33) and control group (n = 33). Both groups were routinely treated with oxygen, anti-infective, anti-shock, and nutritional support, with mechanical ventilation or vasoactive drugs as necessary. Observation group patients with bifidobacterium triple live bacteria enteric-coated capsules 420 mg, 3 times / d, warm water taken from the nasal injection after taking or hydration. The changes of endotoxin, diamine oxidase (DAO) and D-lactate before treatment and after 14 days of treatment were observed in both groups, and their clinical effects were compared. Results After 14 days of treatment, the levels of endotoxin, DAO and D-lactate in both groups were significantly lower than those before (P <0.01 or P <0.05), and the values in the observation group were significantly greater than those in the control group (P <0.05) The total effective rate in observation group was significantly higher than that in control group (χ2 = 3.88, P <0.05). Conclusion Bifidobacterium triple live Enteric-Co-enteric Capsule has good curative effect in adjuvant treatment of patients with severe pneumonia, and can significantly reduce the level of serum endotoxin, DAO and D-lactic acid, relieve endotoxemia and intestinal mucosal permeability, and protect patients Intestinal mucosal barrier function.